No Data
No Data
No Data
No Data
No Data
Gilead Beats Earnings Expectations After Rocky Quarter
After a sell off that saw its shares fall nearly 20% this year, the biotech Gilead Sciences turned in first-quarter results on Thursday that were slightly better than anticipated.
Barron's16:03 ET
Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...
Yahoo Finance39minutes ago
Express News | Gilead : TD Cowen Cuts Target Price to $85 From $90
Reuters01:56 ET
Express News | Gilead : Jefferies Cuts Target Price to $80 From $95
Reuters01:24 ET
Gilead Has Strong Q1, but Updated 2024 EPS Guidance Range Misses Consensus
Seeking Alpha18:55 ET
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
Yahoo Finance18:00 ET
Pumpui : Just buy and hold. The gilead news is worth it. Plus any breakthru in cancer treatment for biohealth will be huge. I am holding
RockaphobicOP Pumpui:
Absolutely! I can't help but feel a bit of confidence. With such promising news, coupled with the fact that Vanguard is one of the 52 institutional shareholders. Sign me up!
GL!
No Data
No Data